Corbus Pharmaceuticals (CRBP) announced the dosing of the first patient in the Phase 1 portion of the clinical study of CRB-601 for the treatment of patients with advanced solid tumors. CRB-601 is a monoclonal antibody targeting latent TGFbeta activation-by blocking the integrin alphaVbeta8. Pre-clinical data has demonstrated that CRB-601 overcomes tumor immune exclusion and enhances the activity of immune checkpoint inhibitors in vivo.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRBP:
- Corbus Pharmaceuticals Advances with FDA Fast Track Designation
- Corbus Pharmaceuticals announces U.S. FDA granted FTD to CRB-701
- Corbus Pharmaceuticals initiated with an Overweight at Piper Sandler
- Corbus Pharmaceuticals Reports Q3 2024 Financials and Updates
- Corbus Pharmaceuticals price target lowered to $75 from $80 at H.C. Wainwright